



2014 Annual General Meeting

28th November 2014

Mr. Richard Hannebery
Chief Executive Officer

Forward Looking Statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements to Genera to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition and our ability to obtain or maintain patent or other proprietary intellectual property protection; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Genera is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Key Achievements last 12 months

- ✓ Sonic Healthcare successful validation of RTI-plex™ and produced robust comparative clinical performance data - sales of RTI-plex™ (RUO) commenced and substantial uplift expected 2015 with regulatory approval.
- ✓ Solid Phase version of PapType™ SP and RTI-plex™ submitted for TGA conformity assessment with both approvals expected early 2015.
- ✓ STI-plex™ development progressed with strong clinical data generated versus leading incumbent assay with commercial launch during 2015.
- ✓ Sirocco automation platform reliability improved and Q-Plots™ analytical software upgraded to be homogenous and seamless for all AmpaSand™ based tests. Also algorithms improved and incorporation of source code allowing use of Genera's FCS.
- ✓ Strategic Commercial Collaboration (SCC) entered into with Beckman Coulter a wholly owned subsidiary of Danaher Corp (NYSE:DHR US\$59 Bn market cap).
 - SCC provides clear path to full AmpaSand™ instrumentation integration and incremental menu expansion to 6-8 MDx assays.
 - Beckman Coulter is Genera's #1 ranked partner of choice with outstanding strategic and cultural fit and post instrumentation integration focus on negotiation and execution of global partnering deal (Genera to retain marketing rights in selected jurisdictions).
- ✓ Additional patents granted during 2014 - IP position strong with Genera now holding a portfolio of 55 granted patents across 9 patent families with a further 60 patents pending

AmpaSand™ – A validated true MDx platform

Objective

Develop and commercialise a diverse menu of compelling multiplexed test solutions for the US\$6Bn global molecular diagnostic testing industry using our silica bead based AmpaSand™ technology platform.

Developments to date – Menu offering = 3 tests with additional menu expansion planned

- ❑ PapType™ HPV detection and genotyping test (TGA, CE-IVD)
 - Projected global market US\$500M+ growing to US\$2,000M+ with widespread screening adoption.
- ❑ PapType™ SP Solid Phase providing labs highly competitive workflow efficiencies (TGA conformity application submitted Sept 2014 with approval expected early CY2015, CE-IVD following shortly thereafter).
- ❑ RTI-plex™ Respiratory pathogens test – 17 plex (TGA conformity application submitted Sept 2014 with approval expected early CY2015, CE-IVD following shortly thereafter).
 - Projected global market US\$200-500M.
- ❑ STI-plex™ Sexually transmitted infections – 5 plex (alpha development completed with beta development finalised end Q2 CY2015).
 - Projected global market US\$350-500M.
- ❑ Objective to add a further 3-5 AmpaSand™ based tests to menu development during 2015.
- ❑ A menu of 6+ AmpaSand™ based tests unequivocally validates high value platform.

Genera has demonstrated its ability to develop high-value low-cost multiplexed MDx

Instrumentation strategy – absolute clarity

Developments to date – Instrumentation

- ❑ Sirocco high volume testing instrument
 - ✓ Demonstrates ability to automate tests run on the AmpaSand™ platform as well as high volume throughput with efficient workflow.
 - ✓ Facilitates commercialisation of developed tests to date with pathology clients in the domestic market.
- ❑ Global exploitation of AmpaSand™ platform requires a global instrumentation partnering relationship
 - ✓ Genera recently entered into Strategic Commercial Collaboration (SCC) with Beckman Coulter (BEC) a wholly owned subsidiary of Danaher Corporation (NYSE:DHR – US\$59 Billion market cap).
 - ✓ SCC >12 months in making and delivers important piece in execution of strategic plan .
 - ✓ SCC positioned to deliver high value additional menu expansion, future global in-market instrumentation support as well as substantial marketing and distribution clout for reagent sales.
- ❑ BEC is the #1 ranked potential partner for Genera for a SCC and subsequent global commercialisation of the AmpaSand™ platform
 - ✓ Outstanding strategic and cultural fit with relationship capable of delivering substantial value to Genera shareholders.
 - ✓ Both parties have clear and unequivocal understanding of roadmap going forward until potential corporate transaction delivered.
- ❑ QPlots™ analytical software also to be integrated with BEC instrumentation firmware.

Genera's AmpaSand platform partnered with leading global IVD is compelling

MDx menu expansion to drive significant value

Ampasand™ platform facilitates high value MDx at circa 70 to 75% gross margin whilst delivering globally competitive pricing

Other tests that may be added to the AmpaSand™ menu with market input of global IVD partner championing voice of customer include:

- HSV1/HSV2
- HCV
- HBV
- CMV
- Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Methicillin-Sensitive Staphylococcus Aureus
- Vancomycin-Resistant Enterococci (VRE) 7
- HIV1/HIV2 Viral Load
- Mycoplasma Pneumoniae
- Chlamydomphila Pneumoniae
- Legionella Pneumophila
- Mycobacterium Tuberculosis
- Gardnerella Vaginalis
- Candida sp.5
- Trichomonas Vaginalis.

Flexibility of Ampasand™ platform to multiplex various combinations of above target analytes in a single test (ie. combining HIV & HCV) to deliver well differentiated offerings providing superior clinical information and patient outcomes.

Other opportunities to grow platform value

Developments to date – Other partnering

- ❑ Genera looking to leverage its AmpaSand™ platform with complementary MDx companies
 - ✓ Strategic commercial alliances can further expand menu offering making customer purchasing decisions easier and more compelling.
 - ✓ Offers Genera additional incremental contribution margin without requisite capital expenditure.
- ❑ Uncovered significant Laboratory Developed Testing (LDT) market opportunity in US for AmpaSand™ based tests
 - ✓ BEC collaboration unlocks major market opportunity from mid-2015 onward.
 - ✓ Existing reimbursement CPT Codes for LDT's highly attractive for RTI-plex™ and STI-plex™ at US\$568 (CPT #87633) and US\$235 (code stacked) respectively = ample margin for customers.
- ❑ Looking to actively pursue non-exclusive distributor relationships in fast growing BRIC markets
 - ✓ India and Brazil attractive offering solid volumes albeit at slightly lower price points.
 - ✓ Low pathology labour costs in BRIC markets mean that level of automation not as key as reagent pricing.

Genera has strict focus on other partnering opportunities being able to add value to our ultimate global IVD partner as this will further add to ultimate Genera shareholder value

Clear 18-24 month plan to build an MDx business with profitable annual revenue run rate > US\$20m delivering > US\$150m market value for shareholders

Recent Developments in HPV Testing

Move to screening indication for HPV testing being driven by Roche with its Cobas™ HPV test

- Based upon screening data showing that strategies that incorporate simultaneous genotyping can increase specificity of an HPV test when incorporated into long term screening.
- Numerous European countries also looking to adopt HPV screening strategy for cervical cancer prevention.
- Genera happily riding Roche's coat tails and its significant investment educating the market about the benefits of simultaneous genotyping in cervical screening.

Australian Renewal of National Cervical Screening Program

- Comprehensive 2 year review by MSAC recommended replacement of traditional pap smear with HPV testing as the primary screening tool.
- Consistent with clear global trend and positions Genera's PapType™ SP well with simultaneous genotyping prerequisite to commercial viability.
 - Number of competitor tests that have established positions in international markets do not meet requirements
- 2016 introduction with universal MBS reimbursement for women 25-69 will immediately grow HPV testing volumes to 1.3m per annum
 - Current HPV test volumes approximately 55k with limited reimbursement set at \$63.55
 - Even with MBS reimbursement declining to ~\$30.00 per test Australian opportunity substantial

PapType™ can be the future proofed HPV test

- ❑ Additional UK Cuzick PapType™ SP clinical trials (Predictors 3 - 6,000 specimens) with Beckman Coulter instrumentation and robust data package will aid wider screening indication for PapType™ SP presenting substantial commercial opportunity.
 - Genera has maintained interest with global HPV KOL (referral initiated by Cuzick) to participate in significant 60,000 patient US study substantially supported by US National Institute of Health – to be commenced post Predictors 3 study results with Beckman Coulter instrumentation.
 - With launch of wider coverage HPV Vaccines (ie. Merck's V503 9-valent HPV vaccine) PapType™ well positioned as the future proofed HPV assay in a vaccine environment.

- ❑ Submitted PapType™ SP information package upon request to Australian Department of Health to assist in determining which HPV tests might be listed on Medicare Benefits Schedule to support the implementation of the proposed cervical screening pathway
 - Changes to National Cervical Screening Program will see HPV testing volumes increase by a factor of >20x in 2016 – Genera's ultimate market penetration aided by potential IVD partnering decision.

MDx World Market


Overall Market Size

World Market for Molecular Diagnostics, 2011 - 2015 (\$M)*

	2011	2012	2013	2014	2015
Blood Screening	918	1,056	1,215	1,397	1,606
HIV/HCV Testing	847	915	988	1,067	1,152
STD Testing	546	611	685	767	859
Oncology Testing	488	576	680	802	947
HPV Testing	353	406	467	537	617
Hospital Infections	116	136	159	186	217
Genetics	480	557	647	750	870
Total	3,748	4,257	4,841	5,506	6,268


MDx World Market

MDx growth driven by increasing demand for accurate infectious disease assays – emerging markets, particularly BRIC experiencing stronger growth (20%+)



KEY TRENDS AND DRIVERS

- MDx (14% CAGR) is the strongest growth driver within the overall IVD market
- Sub-segments of POC testing, including POC MDx and rapid clinic testing, are also growing rapidly
- Emerging markets, particularly in BRIC, experiencing stronger growth (20%+)
- The IVD market is undergoing **consolidation** – an estimated 58 acquisitions¹ were finalized in 2011 (out of 170 for all medical devices and diagnostics²)
- Use of diagnostics supported by **outcomes or cost-effectiveness** studies favored by healthcare reform initiatives (to be discussed)



Source: Scientia analysis, Kalorama, Frost & Sullivan, ¹GenomeWeb, ²Irving Levin Associates

Global MDx market projected to grow at 2x wider IVD market reaching > US\$8Bn in sales by 2018

Summary

- ✓ Demonstrated that AmpaSand™ platform can be used to successfully develop a broad menu of high value multiplexed MDx tests and readily automated to operate efficiently in high volume laboratories.
- ✓ Data obtained by Prof Jack Cuzick who is recognized as a world leader in cervical cancer confirms the clinical performance of both PapType™ and PapType™ SP and the benefits of genotyping HPV.
- ✓ Genera is focussed upon pursuing a complementary partnering deal with a well credentialed global IVD company to maximise market penetration of its AmpaSand™ based MDx platform
 - We have a clear pathway forward via a recent Strategic Commercial Collaboration with Beckman Coulter Inc. a wholly owned subsidiary of Danaher Corporation (NYSE:DHR US\$59 Bn market cap).
- ✓ Genera is cognisant of the latent value of its Q-Sand™ NextGen assets and will in due course explore available opportunities to monetise it to release additional value to shareholders.
- ❑ Possible Commercial Outcomes:
 - IVD company acquires Genera;
 - IVD company acquires rights to AmpaSand™ platform (global & jurisdictional);
 - IVD company and Genera develop JV (global & jurisdictional);
 - Genera installs IVD instrumentation in diagnostic laboratories and supplies AmpaSand™ based MDx tests directly.

All options are on the table - Genera intends to choose optimal path forward by early Q3 CY2015 which may involve one or a mix of the above possible commercial outcomes.

Selected Comparables bode well

Genera Biosystems Acquisition and Trading Comparables

Date	Company	Acquirer	Market Cap	LTM Sales	Multiple	Profitable
Jun-07	Digene Inc	Qiagen N.V.	USD 1,600m	USD 193m	8.3 x	Yes
Jun-08	Thirdwave Technologies Inc	Hologic Inc	USD 580m	USD 34m	17.1 x	No
Jul-08	Innogenetics N.V.	Solvay S.A.	USD 316m	USD 67m	4.7 x	Yes
Oct-08	Molecular Diagnostic Technologies	China Med Technologies Inc	USD 345m	nmf	nmf	No
Jul-11	MTM Labs AG	Roche Diagnostics	USD 270m	nmf	nmf	No
Aug-13	Genmark Diagnostics Inc	N/A currently Nasdaq listed	USD 470m	USD 30m	15.7 x	No
Sep-13	Biofire Diagnostics Inc	BioMerieux S.A.	USD 450m	USD 38m	11.8 x	No
				Median	11.8 x	

Whilst Genera is still early stage and trading pre-material revenue generation selected comparables bode well from a valuation perspective, particularly for platform technologies that have the ability to expand available menu of multiplexed MDx.

Genera has > US\$50million revenue opportunity from AmpaSand™ platform based tests that could be worth > US\$400m to a global IVD partner over the medium term.



For personal use only

Richard Hannebery
richard.hannebery@generabiosystems.com
+61 (3) 9763 1287



Appendices

For personal use only

Target Market – Pathology Laboratories

- ❑ Genera's AmpaSand™ based tests are intended to be used by diagnostic pathology laboratories.
- ❑ Pathology laboratories are in the business of providing information (obtained by analysing patient specimens) to clinicians who use the information to treat their patients.
- ❑ The laboratory business is very competitive and dominated globally by large commercial enterprises.
- ❑ These businesses face continual margin pressure:
 - Payers seek to squeeze reimbursement;
 - High fixed cost operating structures.
- ❑ What factors will a laboratory consider when assessing a new, or replacement, test?
 - ✓ Cost per test;
 - ✓ Labour cost per test;
 - ✓ Turn around time;
 - ✓ Test performance;
 - ✓ Clinical validation;
 - ✓ Clinician demand;
 - ✓ Information provided;
 - ✓ Ease of use;
 - ✓ Equipment requirements.

Target Market – Pathology Laboratories

Why do we believe that diagnostic laboratories will want to use Genera developed diagnostic tests?

Clinical data

- ❑ PapType™ and PapType™ SP (HPV) have both been independently tested by Prof Jack Cuzick and his team at the Wolfson Institute of Preventative Medicine in London (Predictors 2 - 1,099 patient samples) and compared to other commercially available HPV tests.
 - ✓ Ability to genotype HPV is a significant point of difference and the trial data suggests that the accuracy of predicting a patient's risk of disease can be increased with the use of the simultaneous genotyping data.
- ❑ Prof Cuzick's 6,000 patient screening trial - Predictors 3 - comparing PapType™ SP with virtually all other commercial molecular tests on track to be undertaken 2015 (2014 trial delayed due to partnering/instrumentation decision).
 - ✓ Predictors 3 is key study that will support screening indication – already funded.
- ❑ PapType™ SP – ability to genotype and high sensitivity positions well for use as a screening assay.
 - ✓ Genera invited to participate in significant 60,000 US patient study (NIH supported).
- ❑ RTI-plex™ has been clinically validated in circa 3,000 clinical samples to date by Healthscope, Sonic Healthcare and Royal Women's Hospital.

Target Market – Pathology Laboratories

Why do we believe that diagnostic laboratories will want to use Genera developed diagnostic tests?

Operational Performance

- ❑ Multiplexing
 - ✓ Combining multiple tests into a single reaction;
 - ✓ Provides more information per test, allows more informed clinical management;
 - ✓ Results in single assay timeframe;
 - ✓ Streamlines laboratory workflows;
 - ✓ Allows for higher volume batch processing;
 - ✓ Reduces manual handling;
 - ✓ Reduces reagent costs and cost per test;
 - ✓ Multiple assays on one platform reduces instrument requirements/bench space;
 - ✓ Suited to 'coned' reimbursement models although some code stack restrictions being introduced into US.

- ❑ RTI-plex™ and STI-plex™ – extensive analyte panels providing multiple reimbursement streams for pathology labs.

Genera's AmpaSand™ multiplexing MDx platform married with a leading global IVD instrumentation system is a compelling offering for pathology customers

Partnering Process

Strategy

- Direct engagement with diagnostic laboratories.
- Sirocco and test validation agreements qualify AmpaSand™ platform capabilities.
- Leverage diagnostic laboratory interest in existing tests, together with test development potential, underpinned with strong clinical data and IP position.
- Whilst Genera may become profitable as a 'standalone' significant commercial penetration of the global diagnostic lab market can only be made with the involvement of a substantial IVD company.

Current Process

- Commenced in mid-2013 with 5 potential partners identified and engaged.
- Partners ranked #1 to #5 in terms of ideal commercial/cultural fit and attractiveness.
- Strategic Commercial Collaboration (SCC) executed with **Beckman Coulter (Genera's #1 ranked partner)**.
- SCC provides clear pathway over next 3, 5 and 7 months to negotiation and agreement of global licensing and distribution deal.
- Should targeted deal be successfully negotiated significant value can be demonstrated for the AmpaSand™ platform to the benefit of both Genera and BEC shareholders.
- Other targeted partners still viable should acceptable global licensing and distribution deal terms not be reached with BEC with further contingent strategies ready to be put in place.
 - ✓ Genera has an absolute focus on making our BEC relationship work for the benefit of all!

Genera + Beckman Coulter = A compelling position within global MDx market

Partnering Process – lessons learned

Genera has learned valuable lessons from past experiences in partnering process – some comparisons between the 2009/11 process and current 2014/15 include:

- ✓ Whilst Genera's #1 preferred partner is Beckman Coulter (BEC) other partnering options available to generate cash flow and only exclusive upon acceptable global licensing deal being agreed;
- ✓ Core tests developed to date need no material tailoring/customisation to BEC instrumentation platform (a software integration program);
- ✓ Flow cytometry instrumentation platform widely accepted and BEC a global leader of flow solutions;
- ✓ PapType SP™, RTI-plex™ and STI-plex™ tests fill gap in BEC's current offering;
- ✓ BEC has traditional approach to MDx and arguably a significant strategic MDx gap to fill;
- ✓ AmpaSand™ platform can be leveraged by BEC to roll out significant number of complementary MDx tests – a broad MDx menu has high appeal to BEC;
- ✓ BEC's geographic footprint truly global (10,000 employees in 35 countries) and also with focus and capability to successfully penetrate BRIC emerging markets.
- x Potential partner was not the most highly ranked in terms of strategic/commercial and cultural fit;
- x Genera exclusively committed to process with no realistic alternatives to generate material cash flow besides continuing support of shareholders;
- x Due to radical instrumentation approach material re-design of Genera's beads were required;
- x Instrumentation platform was niche to major pathology labs and approach not widely accepted;
- x PapType™ HPV test was an adjunct to their market entry strategy into cervical screening – which was and still remains unproven and unsupported by KOLs and clinicians;
- x Did not leverage other high value aspects of Genera's IP such as the AmpaSand™ platform itself to add additional tests to menu;
- x Whilst had some US and European presence core market was Japan with little focus on emerging markets.

Additional Partnering/Distribution

Genera's previously stated strategy is to engage and partner directly with pathology lab customers where possible

- ❑ Proposed JV with Salomao and Zoppi (Brazil) to address South American market deferred subject to broader discussions with Beckman Coulter.
 - Genera cognisant of not diluting value of South American market rights when greater leverage may exist with a well credentialed global IVD company.

...and also focus on partnering with complementary MDx where it makes sense to do so

- ❑ During 2014 Genera explored a Strategic Commercial Alliance with US based MDx company IncellDx Inc. which has developed a highly complementary HPV 'reflex' test, OncoTect .
 - OncoTect™ has been developed on same instrumentation platform as PapType™ SP;
 - PapType™ SP and OncoTect™ may offer a highly competitive holistic HPV testing algorithm versus Roche's Cobas HPV and its CINtec PLUS Cytology®;
 - IncellDx also developing additional menu in areas of HIV, Breast and Thyroid cancers;
 - Alliance capable of broadening Genera's menu offering beyond AmpaSand™ tests and can be complementary also to preferred global IVD partner;
 - IncellDx relationship to be further progressed during 2015.

Q-Sand™ – NextGen Ultrasensitive Biosensor

Q-Sand™ leverages Genera's core AmpaSand™ Intellectual Property and know how

- ❑ Based upon concept of '*Whispering Gallery Modes*' (WGMs) - a new photonic principle involving discrete measurement of spectral shifts in light/wavelengths providing a unique method for analyte detection - a truly disruptive nanotechnology.
 - Uses Quantum dots (the light source) encased in an outer shell of a silica microsphere (the resonating chamber) measuring the shift in WGMs when outer surface of the silica microsphere shell is modified (the binding event).
 - Leverages Genera's core IP and know how in chemically modifying Silica microspheres to produce custom Quantum dots.
 - Measuring/detecting the shift in the spectral wavelength provides a positive/negative result for a given molecular test (DNA & RNA based).

- ❑ Benefits of Q-Sand™ in MDx:
 - Few operator handling steps;
 - Ease of design and administration;
 - Extremely small volumes of sample required;
 - No fluorescence or radioactive tagging of samples.

Q-Sand™ can potentially provide ultrasensitive label free testing for MDx providing unparalleled multiplexing ability

Q-Sand™ – NextGen Ultrasensitive Biosensor

Q-Sand™ is Genera's next generation ultra sensitive testing platform targeting POC testing market

- ❑ Q-Sand™ can revolutionise traditional approach to MDx with ability to develop ultra-sensitive Point-of-Care (POC) tests.
- ❑ POC testing – the '*elephant in the room*' as it is exact opposite of current pressure for diagnostic labs to consolidate:
 - Ultimate expression of de-centralisation;
 - IVD companies will not ignore the potential of POC market.
- ❑ Key Q-Sand™ patents **granted** in the USA, China, Mexico and NZ:
 - Other key jurisdictions pending to afford widespread coverage in all major jurisdictions;
 - Genera has spent considerable financial resources to date in protecting core Q-Sand™ IP.
- ❑ Comparable technologies have received substantial venture funding from US venture markets
 - Privately held Theranos Inc. successfully raised > US\$100 million in development funding to date.

Genera considering all options for Q-Sand™ including a 'spin-out' involving an in-specie distribution (unlisted) that may be funded with US\$5m start-up capital.

'Spin-out' of the Q-Sand™ assets may be optimal contemporaneous to global licensing of AmpaSand™ mid CY2015

Comparables - background information

Company	Platform technology	Lead test field	Comments
Digene Inc	No	HPV	Acquisition price represented 47.9x LTM EBITDA and gained access to Digene's HC2 HPV testing monopoly at the time. Qiagen was aware of pending competition entering the HPV market at the time of acquisition but believed the eventual estimated HPV testing market size of USD 2 Billion taken with HC2's market leading position could justify the high multiple even in the advent of longer term competitive pricing pressure as well as market share erosion. HPV testing pricing has declined by approximately 30% since and revenues have remained flat even with significant wider market growth
Thirdwave Technologies Inc	No	HPV	At time of acquisition Thirdwave was still pending US FDA approval for its Cervista HR (high risk) HPV assay and Cervista 16/18 limited genotyping assay. The HR HPV assay held an advantage of lower QNS results versus Digene's HC2 and also had an internal control. Invader technology platform on which the assays were built limited other applications. FDA approval eventually received 2009. Based upon acquisition price Hologic required to achieve approximately 20 to 25% market share in HPV testing to justify consideration paid.
Innogenetics N.V.	Yes	HPV	Innogenetics had developed a 14 high risk type HPV genotyping assay that had CE Mark status but was yet to be approved by FDA. Final acquisition price was a 74% uplift to pre-bid value. Bid involved 2 way competitive bidding between Solvay and Gen-Probe with Gen-Probe acquired by Hologic in 2012. Corporate interest driven by LiPA multiplexing platform that accounted for approx 54% of LTM revenue. Other revenues driven by older diagnostic technologies with low gross margin. Overall gross margin running at 54%.
Molecular Diagnostic Technologies Ltd	No	HPV	HPV test still in early development stage using surface plasmon resonance - unproven in human MDx
MTM Labs AG	No	HPV	Acquired by Roche as a hedge for its HPV franchise. Roche received US FDA clearance for its own internally developed Cobas HR simultaneous 16/18 genotyping HPV test in early 2011. The MTM Labs HPV test provides significantly higher specificity testing for p-16k protein but has a sensitivity performance under the 90% threshold deemed acceptable for a HPV screening assay
Genmark Diagnostics Inc	Yes	Respiratory	IPO in June 2011 at a mkt cap of USD 90m raising USD 30m under the IPO. In August 2013 via a follow-on raised US\$75m at valuation of \$400m to support further development of its Next Gen AD-8 multiplexing platform. Technology enables detection of up to 72 distinct biomarkers in a single sample. Its XT-8 System has received 510(k) clearance from FDA. Has rapid results TAT of approx 30 minutes. Low volume throughput suited to acute care hospital settings and not high volume pathology labs.
Biofire Diagnostics Inc	Yes	Respiratory	PCR technology has developed a number of PCR-based automated diagnostic systems used in hospital laboratories. Its multiplex PCR FilmArray platform \$38m sales CY2013. BioFire's first significant diagnostic launched commercially is a rapid TAT respiratory panel that tests for 20 viruses and bacteria and delivers the results in one hour. Cleared for use in both Europe and the United States. In June 2013 received FDA clearance to market a sepsis panel. Low volume throughput platform suited to acute care hospital settings and not high volume pathology labs.